The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 05, 2019
Filed:
Feb. 06, 2017
Applicant:
Modernatx, Inc., Cambridge, MA (US);
Inventors:
Antonin De Fougerolles, Waterloo, BE;
Justin Guild, Framingham, MA (US);
Assignee:
ModernaTX, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 31/7115 (2006.01); A61K 38/17 (2006.01); A61K 47/54 (2017.01); A61K 9/127 (2006.01); C07K 14/005 (2006.01); C12N 15/11 (2006.01); C12N 9/00 (2006.01); C12N 15/85 (2006.01); C07K 14/47 (2006.01); C07K 14/62 (2006.01); C12N 9/88 (2006.01); C07K 14/705 (2006.01); C07K 14/505 (2006.01); C07K 14/535 (2006.01); C12N 9/64 (2006.01); C12N 9/10 (2006.01); C12N 9/42 (2006.01); C12N 15/87 (2006.01); C12P 13/04 (2006.01); A61K 38/45 (2006.01); C12N 9/16 (2006.01); C12N 9/24 (2006.01); C12N 15/52 (2006.01); C07K 14/435 (2006.01); C12P 21/00 (2006.01); C07K 14/485 (2006.01); C07H 21/02 (2006.01); C07K 14/475 (2006.01); C07K 14/495 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); C07K 14/56 (2006.01); C07K 14/61 (2006.01); C07K 14/745 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 9/02 (2006.01); C12N 9/12 (2006.01); C12N 9/68 (2006.01); A61K 9/14 (2006.01); A61K 9/51 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 38/48 (2006.01); C07K 14/515 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 9/1271 (2013.01); A61K 9/145 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 31/7115 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1816 (2013.01); A61K 38/1891 (2013.01); A61K 38/191 (2013.01); A61K 38/193 (2013.01); A61K 38/212 (2013.01); A61K 38/45 (2013.01); A61K 38/4846 (2013.01); A61K 47/543 (2017.08); A61K 48/005 (2013.01); A61K 48/0033 (2013.01); A61K 48/0075 (2013.01); C07H 21/02 (2013.01); C07K 14/005 (2013.01); C07K 14/435 (2013.01); C07K 14/43595 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 14/4705 (2013.01); C07K 14/4713 (2013.01); C07K 14/4723 (2013.01); C07K 14/4746 (2013.01); C07K 14/485 (2013.01); C07K 14/495 (2013.01); C07K 14/505 (2013.01); C07K 14/515 (2013.01); C07K 14/525 (2013.01); C07K 14/535 (2013.01); C07K 14/5418 (2013.01); C07K 14/56 (2013.01); C07K 14/61 (2013.01); C07K 14/62 (2013.01); C07K 14/705 (2013.01); C07K 14/745 (2013.01); C07K 16/00 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/40 (2013.01); C12N 9/0069 (2013.01); C12N 9/0091 (2013.01); C12N 9/1051 (2013.01); C12N 9/1241 (2013.01); C12N 9/16 (2013.01); C12N 9/2402 (2013.01); C12N 9/2445 (2013.01); C12N 9/644 (2013.01); C12N 9/6435 (2013.01); C12N 9/6437 (2013.01); C12N 9/6443 (2013.01); C12N 9/6451 (2013.01); C12N 9/88 (2013.01); C12N 9/93 (2013.01); C12N 15/11 (2013.01); C12N 15/52 (2013.01); C12N 15/85 (2013.01); C12N 15/87 (2013.01); C12P 13/04 (2013.01); C12P 21/00 (2013.01); C12P 21/005 (2013.01); C12Y 603/02019 (2013.01); A61K 38/00 (2013.01); C12Y 113/12007 (2013.01); C12Y 116/03001 (2013.01); C12Y 207/07012 (2013.01); C12Y 304/21007 (2013.01); C12Y 304/21022 (2013.01); C12Y 304/21027 (2013.01); C12Y 403/02001 (2013.01); Y02A 50/401 (2018.01); Y02A 50/411 (2018.01); Y02A 50/414 (2018.01); Y02A 50/415 (2018.01); Y02A 50/423 (2018.01); Y02A 50/463 (2018.01); Y02A 50/491 (2018.01);
Abstract
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.